Key Points
- Derek Maetzold sold 6,214 Castle Biosciences shares at an average price of $25.03 on April 6 for $155,536, cutting his position by 22.44% to 21,479 shares; the sale was executed under a Rule 10b5-1 plan.
- Castle reported Q4 EPS of ($0.08) versus estimates of ($0.23) with revenue of $81.88M, and the stock trades around $25.19 with a one‑year range of $14.59–$44.28 and a market cap of about $748.9M.
- Analysts rate CSTL a Moderate Buy (8 Buys, 1 Hold, 1 Sell) with an average price target of $47.57, and institutional investors own roughly 92.6% of the shares.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 6,214 shares of the business's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $25.03, for a total value of $155,536.42. Following the completion of the transaction, the insider owned 21,479 shares in the company, valued at $537,619.37. This trade represents a 22.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Stock Performance
Shares of NASDAQ CSTL opened at $25.19 on Thursday. The business's 50-day moving average price is $29.01 and its two-hundred day moving average price is $31.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.26 and a quick ratio of 5.11. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The company has a market capitalization of $748.90 million, a P/E ratio of -29.64 and a beta of 1.18.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The firm had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. Analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Institutional Trading of Castle Biosciences
Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter worth about $26,000. Farther Finance Advisors LLC lifted its position in shares of Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company's stock worth $32,000 after buying an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Castle Biosciences in the third quarter worth about $35,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter worth about $35,000. Finally, CWM LLC lifted its position in shares of Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company's stock worth $44,000 after buying an additional 853 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have commented on CSTL shares. Lake Street Capital boosted their target price on Castle Biosciences from $35.00 to $52.00 and gave the company a "buy" rating in a research note on Monday, January 12th. Canaccord Genuity Group boosted their target price on Castle Biosciences from $37.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, December 22nd. KeyCorp restated an "overweight" rating and issued a $50.00 target price on shares of Castle Biosciences in a research note on Thursday, January 29th. Robert W. Baird boosted their target price on Castle Biosciences from $41.00 to $44.00 and gave the company an "outperform" rating in a research note on Friday, February 27th. Finally, BTIG Research boosted their target price on Castle Biosciences from $38.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Castle Biosciences has an average rating of "Moderate Buy" and an average price target of $47.57.
Read Our Latest Report on CSTL
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
